Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fiona M Ross

Showing results (21-30 of 57) with videos related to

Pageof 6
Sort By:
Blood|February 26, 2013
Characterization of IGH locus breakpoints in multiple myeloma indicates a subset of translocations appear to occur in pregerminal center B cellsBrian A Walker, Christopher P Wardell, David C Johnson, et al.
Haematologica|April 23, 2010
The t(14;20) is a poor prognostic factor in myeloma but is associated with long-term stable disease in monoclonal gammopathies of undetermined significanceFiona M Ross, Laura Chiecchio, GianPaolo Dagrada, et al.
British Journal of Haematology|January 30, 2013
Response and biological subtype of myeloma are independent prognostic factors and combine to define outcome after high-dose therapyAnnamaria Brioli, Kevin D Boyd, Martin F Kaiser, et al.
Haematologica|December 10, 2009
Timing of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic contextLaura Chiecchio, Gian Paolo Dagrada, Ashraf H Ibrahim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 3, 2013
Long-term follow-up of MRC Myeloma IX trial: Survival outcomes with bisphosphonate and thalidomide treatmentGareth J Morgan, Faith E Davies, Walter M Gregory, et al.
Haematologica|December 9, 2008
MMSET deregulation affects cell cycle progression and adhesion regulons in t(4;14) myeloma plasma cellsJose L R Brito, Brian Walker, Matthew Jenner, et al.
Genes, Chromosomes & Cancer|April 28, 2009
Frequent upregulation of MYC in plasma cell leukemiaLaura Chiecchio, Gian Paolo Dagrada, Helen E White, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 8, 2010
Heterogeneity in the prognostic significance of 12p deletion and chromosome 5 amplification in multiple myelomaWilliam Tapper, Laura Chiecchio, Gian Paolo Dagrada, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|June 18, 2011
Gender disparities in the tumor genetics and clinical outcome of multiple myelomaKevin D Boyd, Fiona M Ross, Laura Chiecchio, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 30, 2008
Variable breakpoints target PAX5 in patients with dicentric chromosomes: a model for the basis of unbalanced translocations in cancerQian An, Sarah L Wright, Zoë J Konn, et al.
Pageof 6

Showing results (21-30 of 57) with videos related to

Sort By:
Pageof 6
Blood|February 26, 2013
Characterization of IGH locus breakpoints in multiple myeloma indicates a subset of translocations appear to occur in pregerminal center B cellsBrian A Walker, Christopher P Wardell, David C Johnson, et al.
Haematologica|April 23, 2010
The t(14;20) is a poor prognostic factor in myeloma but is associated with long-term stable disease in monoclonal gammopathies of undetermined significanceFiona M Ross, Laura Chiecchio, GianPaolo Dagrada, et al.
British Journal of Haematology|January 30, 2013
Response and biological subtype of myeloma are independent prognostic factors and combine to define outcome after high-dose therapyAnnamaria Brioli, Kevin D Boyd, Martin F Kaiser, et al.
Haematologica|December 10, 2009
Timing of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic contextLaura Chiecchio, Gian Paolo Dagrada, Ashraf H Ibrahim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 3, 2013
Long-term follow-up of MRC Myeloma IX trial: Survival outcomes with bisphosphonate and thalidomide treatmentGareth J Morgan, Faith E Davies, Walter M Gregory, et al.
Haematologica|December 9, 2008
MMSET deregulation affects cell cycle progression and adhesion regulons in t(4;14) myeloma plasma cellsJose L R Brito, Brian Walker, Matthew Jenner, et al.
Genes, Chromosomes & Cancer|April 28, 2009
Frequent upregulation of MYC in plasma cell leukemiaLaura Chiecchio, Gian Paolo Dagrada, Helen E White, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 8, 2010
Heterogeneity in the prognostic significance of 12p deletion and chromosome 5 amplification in multiple myelomaWilliam Tapper, Laura Chiecchio, Gian Paolo Dagrada, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|June 18, 2011
Gender disparities in the tumor genetics and clinical outcome of multiple myelomaKevin D Boyd, Fiona M Ross, Laura Chiecchio, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 30, 2008
Variable breakpoints target PAX5 in patients with dicentric chromosomes: a model for the basis of unbalanced translocations in cancerQian An, Sarah L Wright, Zoë J Konn, et al.
Pageof 6